Could a gene test spare some breast cancer patients from radiation?

NCT ID NCT02653755

Ongoing Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

The PRECISION trial is studying whether women with a specific type of early-stage breast cancer can safely avoid radiation therapy after having a lumpectomy. Participants have tumors that are small, hormone receptor-positive, HER2-negative, and low-grade. A gene test called Prosigna helps identify those at very low risk of recurrence. The goal is to see if the cancer returns in the same breast within five years without radiation. This research could help personalize treatment and spare some women from unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prosigna (PAM-50) gene test
What this could lead to: If successful, this could show that some women with early-stage, low-risk breast cancer can avoid radiotherapy after lumpectomy, reducing side effects and treatment burden.
What could go wrong: This is a phase 2 study, so results are preliminary. It's possible that skipping radiotherapy may lead to a higher risk of cancer returning in the breast, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER RADIATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER RADIATION

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloane Kettering Cancer Center

New York, New York, 10065, United States
NYU Langone Health

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.